Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma.
Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma.
复制标题
DOI：
10.1158/1078-0432.ccr-08-0498
复制
发表时间：
2008-11-01
影响因子：
11.5
通讯作者：
Gillison, Maura L.
中科院分区：
文献类型：
--
作者：
Agrawal, Yuri;Koch, Wayne M.;Xiao, Weihong;Westra, William H.;Trivett, Anna L.;Symer, David E.;Gillison, Maura L.
口腔人乳头瘤病毒（HPV）感染是头颈部鳞状细胞癌（HNSCC）的危险因素，是HPV阳性HNSCC患者及其伴侣关注的问题。研究了hpv16阳性和阴性HNSCC患者在癌症治疗前后口腔HPV感染的患病率。从135例HNSCC患者队列中收集连续口腔冲洗样本（ORS），频率为每三个月一次，长达三年。采用HPV16原位杂交法检测肿瘤的HPV状态。采用一致性PCR和线印迹杂交检测ORS中HPV。阳性口腔冲洗-肿瘤配对中HPV16变异通过测序确定。使用广义估计方程比较hpv16阳性和阴性病例中口腔HPV感染的几率。患者随访时间中位数为21个月，中位数为4个样本。135例患者中有44例hpv16阳性肿瘤。hpv16阳性患者治疗前（OR=8.6, 95%CI=3.5 ~ 21）和治疗后（OR=2.9, 95%CI=1.1 ~ 7.4）口腔HPV感染检出率高于hpv16阴性患者。在HPV16阳性患者治疗前后，HPV16及其他高危而非低危型口腔感染更为常见。ORS中的大多数HPV16变异是欧洲的，独特的，与肿瘤中的相同。类型特异性口腔感染的持续时间可达5年之久。口腔高危HPV感染在hpv16阳性HNSCC患者中比hpv16阴性HNSCC患者中更常见，这与感染的行为和/或生物学倾向相一致。
Oral human papillomavirus (HPV) infection is a risk factor for head and neck squamous cell carcinoma (HNSCC), and is a concern for patients with HPV-positive HNSCC and their partners. The prevalence of oral HPV infection before and after cancer therapy was investigated among patients with HPV16-positive and -negative HNSCC. Serial oral rinse samples (ORS) were collected from a cohort of 135 HNSCC cases as frequently as every three months for up to three years. Tumor HPV status was determined by HPV16 in situ hybridization. HPV was detected in ORS by consensus PCR and line-blot hybridization. The HPV16 variants in positive oral rinse-tumor pairs were determined by sequencing. The odds of oral HPV infection among HPV16-positive and -negative cases were compared by use of generalized estimating equations. Patients were followed for a median of 21 months and provided a median of four samples. Forty-four of 135 patients had HPV16-positive tumors. HPV16-positive cases were more likely than HPV16-negative cases to have an oral HPV infection detected before (OR=8.6, 95%CI=3.5–21) and after therapy (OR=2.9, 95%CI=1.1–7.4). Oral infections by HPV16 and other high-risk, but not low-risk, types were more common among HPV16-positive cases both before and after therapy. Most HPV16 variants in ORS were European, unique, and identical to that in the tumor. Persistence of a type-specific oral infection was demonstrable for as long as five years. Oral high-risk HPV infections are more frequent among patients with HPV16-positive than HPV16-negative HNSCC, consistent with a behavioral and/or biological disposition to infection.